+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market - Global Forecast 2026-2032- Product Image
Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market - Global Forecast 2026-2032

  • Report

  • 198 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6147462
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market is projected to reach USD 1.39 Billion in 2026. It is expected to continue growing at a CAGR of 4.99%, reaching USD 1.85 Billion by 2032.

Introduction to Monoclonal Antibody Anti-VEGF Ophthalmic Drugs

Monoclonal antibody anti-VEGF ophthalmic drugs inhibit vascular endothelial growth factor to reduce abnormal blood-vessel formation and vascular leakage in retinal diseases. Their clinical use is established across conditions such as neovascular age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. Treatment value depends on diagnostic access, injection capacity, product selection, adherence, reimbursement, and the ability of providers to monitor disease activity over time.

Transformative Shifts Reshaping Retinal Care

Retinal care is shifting from episodic treatment toward protocol-driven, longitudinal management supported by imaging and disease-activity assessment. Longer-acting formulations, biosimilar adoption, treat-and-extend regimens, and improvements in injection workflows are influencing how clinicians balance durability, safety, access, and treatment burden. Earlier referral, expanded screening for diabetic eye disease, and better coordination between primary care, endocrinology, and ophthalmology are also becoming increasingly important.

How Artificial Intelligence Is Changing Anti-VEGF Delivery

Artificial intelligence is being applied to retinal image interpretation, disease detection, treatment-response assessment, and workflow prioritization. These tools can help identify patients requiring specialist review and support consistency in monitoring, but their clinical value depends on representative training data, external validation, explainability, cybersecurity, and integration with existing imaging systems. AI is most useful as decision support rather than a substitute for clinician judgment, particularly when treatment decisions involve comorbidities, uncertain findings, or atypical disease.

Regional Insights Across Global Retinal-Care Systems

North America benefits from advanced imaging, specialist infrastructure, and relatively broad access to biologic therapies, while affordability and injection frequency remain important concerns. Europe combines strong clinical capabilities with varied reimbursement rules, health-technology assessment requirements, and differing biosimilar policies across countries. Asia-Pacific presents substantial unmet need alongside uneven screening, specialist availability, and rural access; Japan, China, South Korea, Australia, and India reflect distinct regulatory and care-delivery environments. Latin America continues to face disparities in diagnosis, public-sector funding, and treatment continuity. The Middle East is developing specialist capacity and referral networks, particularly in higher-resource health systems, while Africa faces pronounced constraints in screening, ophthalmic workforce availability, diagnostic equipment, and sustained access to treatment.

Group Insights: ASEAN, BRICS, EU, G7, GCC, and NATO

ASEAN markets are characterized by diverse reimbursement systems, urban-rural access gaps, and growing demand for diabetic-retinopathy and age-related macular-degeneration services. BRICS economies combine large patient populations with varied public procurement models, domestic manufacturing capabilities, and uneven specialist coverage. European Union systems emphasize regulatory compliance, comparative assessment, and coordinated approaches to biosimilars, although national reimbursement decisions remain decisive. G7 members generally have mature retinal services, but face aging populations, workforce pressure, and the need to control treatment burden. GCC countries are investing in advanced hospitals and specialist services, while NATO members collectively span highly developed and resource-constrained systems, making access, procurement, and clinical-capacity conditions heterogeneous.

Country Insights Across Fifteen Priority Markets

Australia and Canada have sophisticated retinal services but must address geographic dispersion and treatment access outside major centers. Brazil and Mexico face substantial regional differences in public and private care capacity. China is expanding ophthalmic infrastructure and local pharmaceutical capabilities, while India combines strong specialist centers with significant rural and affordability barriers. Japan, South Korea, France, Germany, Italy, Spain, and the United Kingdom have established clinical pathways, with reimbursement, biosimilar uptake, waiting times, and workforce capacity shaping utilization. The United States has extensive diagnostic and specialist infrastructure, alongside complex coverage and administration considerations. Russia’s access environment is influenced by procurement, regulatory, and health-system conditions that can vary over time.

Actions for Leaders to Improve Access and Outcomes

Industry leaders should prioritize evidence that connects treatment durability, real-world adherence, safety, and patient-reported burden with clinically meaningful outcomes. Access strategies should reflect local reimbursement, public procurement, cold-chain capability, and rural delivery constraints rather than relying on a single global model. Partnerships with providers can strengthen screening, referral, injection capacity, and follow-up. Leaders should also prepare transparent evidence standards for AI-enabled tools, support responsible biosimilar education, and invest in patient communication that explains the importance of monitoring and continuity of care.

Research Methodology for the Executive Summary

This executive summary uses the defined market scope of monoclonal antibody anti-VEGF ophthalmic drugs and organizes findings by therapeutic practice, care delivery, technology, geography, and health-system grouping. Insights are based on established clinical applications, publicly documented regulatory and reimbursement considerations, peer-reviewed evidence, health-system information, and recognized patterns in ophthalmic service delivery. The assessment is qualitative and deliberately excludes market estimates, market sizing, market shares, forecasts, and unsupported company-specific claims.

Conclusion: Building More Durable and Equitable Retinal Care

Monoclonal antibody anti-VEGF ophthalmic drugs remain central to the management of several vision-threatening retinal diseases, but outcomes depend on more than pharmacology. Earlier detection, reliable imaging, adequate injection capacity, sustainable reimbursement, and patient adherence determine whether clinical potential is realized. Regional and country differences require locally adapted strategies, while AI, biosimilars, and longer-acting approaches should be adopted with rigorous validation and attention to equity. Leaders that connect innovation with practical care delivery will be better positioned to improve continuity and preserve vision.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market, by Product
7.1. Introduction
7.2. Aflibercept
7.3. Bevacizumab
7.4. Brolucizumab
7.5. Ranibizumab
8. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market, by Indication
8.1. Introduction
8.2. Diabetic Macular Edema
8.3. Diabetic Retinopathy
8.4. Retinal Vein Occlusion
8.5. Wet Age Related Macular Degeneration
9. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market, by Type
9.1. Introduction
9.2. Biosimilar
9.3. Branded
10. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market, by Dosage Form
10.1. Introduction
10.2. Prefilled Syringe
10.3. Vial
11. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market, by End Use
11.1. Introduction
11.2. Ambulatory Surgical Center
11.3. Hospital Ophthalmology Clinic
11.4. Specialty Eye Hospital
12. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Bayer AG
16.2. Biocon Limited
16.3. Biogen Inc.
16.4. Coherus BioSciences, Inc.
16.5. F. Hoffmann-La Roche Ltd
16.6. INTAS PHARMACEUTICALS LIMITED
16.7. Novartis AG
16.8. Pfizer Inc.
16.9. Regeneron Pharmaceuticals, Inc.
16.10. Samsung Bioepis Co., Ltd.
16.11. Sandoz International GmbH
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market, Years Considered for the Study
FIGURE 2. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market, Research Design
FIGURE 3. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market, Research Framework
FIGURE 4. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market, Data Triangulation
FIGURE 5. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Product, 2025 vs 2032 (%)
FIGURE 7. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Product, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 9. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Type, 2025 vs 2032 (%)
FIGURE 11. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Dosage Form, 2025 vs 2032 (%)
FIGURE 13. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Dosage Form, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by End Use, 2025 vs 2032 (%)
FIGURE 15. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by End Use, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Segmentation & Coverage
TABLE 2. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, 2017-2032 (USD Million)
TABLE 3. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 4. Global Aflibercept Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Aflibercept Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Aflibercept Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Bevacizumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Bevacizumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Bevacizumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Brolucizumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Brolucizumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Brolucizumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Ranibizumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Ranibizumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Ranibizumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 17. Global Diabetic Macular Edema Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Diabetic Macular Edema Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Diabetic Macular Edema Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Diabetic Retinopathy Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Diabetic Retinopathy Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Diabetic Retinopathy Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Retinal Vein Occlusion Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Retinal Vein Occlusion Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Retinal Vein Occlusion Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Wet Age Related Macular Degeneration Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Wet Age Related Macular Degeneration Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Wet Age Related Macular Degeneration Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Type, 2017-2032 (USD Million)
TABLE 30. Global Biosimilar Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Biosimilar Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Biosimilar Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Branded Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Branded Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Branded Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 37. Global Prefilled Syringe Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Prefilled Syringe Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Prefilled Syringe Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Vial Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Vial Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Vial Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by End Use, 2017-2032 (USD Million)
TABLE 44. Global Ambulatory Surgical Center Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Ambulatory Surgical Center Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Ambulatory Surgical Center Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Hospital Ophthalmology Clinic Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Hospital Ophthalmology Clinic Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Hospital Ophthalmology Clinic Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Specialty Eye Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Specialty Eye Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Specialty Eye Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Asia-Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Asia-Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 56. Asia-Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 57. Asia-Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Type, 2017-2032 (USD Million)
TABLE 58. Asia-Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 59. Asia-Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by End Use, 2017-2032 (USD Million)
TABLE 60. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 62. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 63. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Type, 2017-2032 (USD Million)
TABLE 64. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 65. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by End Use, 2017-2032 (USD Million)
TABLE 66. Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 68. Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 69. Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Type, 2017-2032 (USD Million)
TABLE 70. Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 71. Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by End Use, 2017-2032 (USD Million)
TABLE 72. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 74. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 75. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Type, 2017-2032 (USD Million)
TABLE 76. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 77. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by End Use, 2017-2032 (USD Million)
TABLE 78. Middle East Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Middle East Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 80. Middle East Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 81. Middle East Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Type, 2017-2032 (USD Million)
TABLE 82. Middle East Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 83. Middle East Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by End Use, 2017-2032 (USD Million)
TABLE 84. Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 85. Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 86. Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 87. Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Type, 2017-2032 (USD Million)
TABLE 88. Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 89. Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by End Use, 2017-2032 (USD Million)
TABLE 90. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 91. ASEAN Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 92. ASEAN Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 93. ASEAN Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 94. ASEAN Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Type, 2017-2032 (USD Million)
TABLE 95. ASEAN Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 96. ASEAN Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by End Use, 2017-2032 (USD Million)
TABLE 97. GCC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 98. GCC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 99. GCC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 100. GCC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Type, 2017-2032 (USD Million)
TABLE 101. GCC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 102. GCC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by End Use, 2017-2032 (USD Million)
TABLE 103. European Union Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 104. European Union Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 105. European Union Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 106. European Union Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Type, 2017-2032 (USD Million)
TABLE 107. European Union Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 108. European Union Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by End Use, 2017-2032 (USD Million)
TABLE 109. BRICS Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 110. BRICS Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 111. BRICS Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 112. BRICS Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Type, 2017-2032 (USD Million)
TABLE 113. BRICS Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 114. BRICS Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by End Use, 2017-2032 (USD Million)
TABLE 115. G7 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 116. G7 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 117. G7 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 118. G7 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Type, 2017-2032 (USD Million)
TABLE 119. G7 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 120. G7 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by End Use, 2017-2032 (USD Million)
TABLE 121. NATO Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 122. NATO Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 123. NATO Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 124. NATO Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Type, 2017-2032 (USD Million)
TABLE 125. NATO Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 126. NATO Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by End Use, 2017-2032 (USD Million)
TABLE 127. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 128. United States Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, 2017-2032 (USD Million)
TABLE 129. United States Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 130. United States Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 131. United States Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Type, 2017-2032 (USD Million)
TABLE 132. United States Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 133. United States Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by End Use, 2017-2032 (USD Million)
TABLE 134. Canada Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, 2017-2032 (USD Million)
TABLE 135. Canada Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 136. Canada Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 137. Canada Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Type, 2017-2032 (USD Million)
TABLE 138. Canada Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 139. Canada Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by End Use, 2017-2032 (USD Million)
TABLE 140. Mexico Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, 2017-2032 (USD Million)
TABLE 141. Mexico Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 142. Mexico Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 143. Mexico Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Type, 2017-2032 (USD Million)
TABLE 144. Mexico Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 145. Mexico Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by End Use, 2017-2032 (USD Million)
TABLE 146. Brazil Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, 2017-2032 (USD Million)
TABLE 147. Brazil Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 148. Brazil Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 149. Brazil Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Type, 2017-2032 (USD Million)
TABLE 150. Brazil Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 151. Brazil Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by End Use, 2017-2032 (USD Million)
TABLE 152. United Kingdom Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, 2017-2032 (USD Million)
TABLE 153. United Kingdom Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 154. United Kingdom Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 155. United Kingdom Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Type, 2017-2032 (USD Million)
TABLE 156. United Kingdom Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 157. United Kingdom Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by End Use, 2017-2032 (USD Million)
TABLE 158. Germany Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, 2017-2032 (USD Million)
TABLE 159. Germany Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 160. Germany Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 161. Germany Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Type, 2017-2032 (USD Million)
TABLE 162. Germany Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 163. Germany Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by End Use, 2017-2032 (USD Million)
TABLE 164. France Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, 2017-2032 (USD Million)
TABLE 165. France Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 166. France Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 167. France Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Type, 2017-2032 (USD Million)
TABLE 168. France Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 169. France Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by End Use, 2017-2032 (USD Million)
TABLE 170. Russia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, 2017-2032 (USD Million)
TABLE 171. Russia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 172. Russia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 173. Russia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Type, 2017-2032 (USD Million)
TABLE 174. Russia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 175. Russia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by End Use, 2017-2032 (USD Million)
TABLE 176. Italy Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, 2017-2032 (USD Million)
TABLE 177. Italy Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 178. Italy Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 179. Italy Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Type, 2017-2032 (USD Million)
TABLE 180. Italy Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 181. Italy Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by End Use, 2017-2032 (USD Million)
TABLE 182. Spain Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, 2017-2032 (USD Million)
TABLE 183. Spain Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 184. Spain Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 185. Spain Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Type, 2017-2032 (USD Million)
TABLE 186. Spain Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 187. Spain Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by End Use, 2017-2032 (USD Million)
TABLE 188. China Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, 2017-2032 (USD Million)
TABLE 189. China Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 190. China Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 191. China Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Type, 2017-2032 (USD Million)
TABLE 192. China Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 193. China Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by End Use, 2017-2032 (USD Million)
TABLE 194. India Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, 2017-2032 (USD Million)
TABLE 195. India Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 196. India Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 197. India Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Type, 2017-2032 (USD Million)
TABLE 198. India Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 199. India Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by End Use, 2017-2032 (USD Million)
TABLE 200. Japan Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, 2017-2032 (USD Million)
TABLE 201. Japan Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 202. Japan Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 203. Japan Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Type, 2017-2032 (USD Million)
TABLE 204. Japan Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 205. Japan Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by End Use, 2017-2032 (USD Million)
TABLE 206. Australia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, 2017-2032 (USD Million)
TABLE 207. Australia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 208. Australia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 209. Australia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Type, 2017-2032 (USD Million)
TABLE 210. Australia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 211. Australia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by End Use, 2017-2032 (USD Million)
TABLE 212. South Korea Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, 2017-2032 (USD Million)
TABLE 213. South Korea Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 214. South Korea Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 215. South Korea Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Type, 2017-2032 (USD Million)
TABLE 216. South Korea Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 217. South Korea Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size, by End Use, 2017-2032 (USD Million)
TABLE 218. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Share, by Key Player, 2025
TABLE 219. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market, Key Experts

Companies Mentioned

  • Bayer AG
  • Biocon Limited
  • Biogen Inc.
  • Coherus BioSciences, Inc.
  • F. Hoffmann-La Roche Ltd
  • INTAS PHARMACEUTICALS LIMITED
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Samsung Bioepis Co., Ltd.
  • Sandoz International GmbH

Related Topics

Related Reports

Monoclonal Antibody VEGF Inhibitors Market - Global Forecast 2026-2032 - Product Image

Monoclonal Antibody VEGF Inhibitors Market - Global Forecast 2026-2032

  • Report
  • 188 Pages
  • Global
From
Cancer Monoclonal Antibodies Market - Global Forecast 2026-2032 - Product Image

Cancer Monoclonal Antibodies Market - Global Forecast 2026-2032

  • Report
  • 186 Pages
  • Global
From
Monoclonal Antibody Therapeutics Market Report 2026 - Product Image

Monoclonal Antibody Therapeutics Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Bispecific Antibodies Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Therapeutic Area, Mechanism of Action, Target Antigen Antibody Format, Key Geographical Regions and Key Players - Product Image

Bispecific Antibodies Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Therapeutic Area, Mechanism of Action, Target Antigen Antibody Format, Key Geographical Regions and Key Players

  • Report
  • 391 Pages
  • Global
From
Antibody Therapeutics Market by Product, Format, Target, Therapy area, Source, RoA, Region, Competition - Global Forecast to 2035 - Product Image

Antibody Therapeutics Market by Product, Format, Target, Therapy area, Source, RoA, Region, Competition - Global Forecast to 2035

  • Report
  • 517 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.